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ABOUT THE IPTS REPORT
lhe tm ReOon was huncbed in December 195, on tbe requ.est ond under tbe auspices of CommissionerI Cresson. Wbat seemed like a daunting chalbnge in hte 1995, nou oppears in reffowct as a crucial
galuaniser of tbe IPTS' energies and shilb.
Tbe Report bas publisbed articles in nutnerous areas, maintaining a rougb balance beWeen tbem, and
exploiting interdisciplinarity as far as Nssible. Articles are deemed prospectiuely releuant if they attenpt to
explore issues not Wt on tbe polkynaker agmda (but projected to be tbere s@ner or later), or
underappreciated aspecs oJ issues already on the policryaker's agenda. The long drafiing and redrafting
process, based on a series of interactiue consultations with outside etp* guaranteeq quality control.
Tbe firct, and possibly most significan, indkator, of success is tbat tbe Report is being read. Tbe issue 00
(December 1999 bad aprint run of 2000 copies, in what seemed an optirnistic projection at the tirne. Since
tben, its circulation bas bem boosted ta 7000 copies. Requestsfor subscriptions baue come not onlyfrom
uarious parts of Europe but abofron tbe US, Japan, Australia, Latin America, N. Africa, etc.
Tbe laureb tbe publir,atian is reaping are rendering it attractile for autbon fron outside tbe Commission.
We baue already published contributiors by autborcfrom such renouned institutions as tbe Dutcb TNO, tbe
German WI, tbe ltalian ENEAand tbe US Council of Strategic and International Studies.
Moreouer, tbe IPTS formally collaborates on tbe productian of tbe IP(S Report uilb a group of prestigious
European institutians, ulitb ubom the IPN bas formed the European Science and Tecbnologlt Obsentatory
(FSTO), an inpofiant pan of tbe remit of the IPIS. The IPIS Report is the most uisible manife§ation of tbis
collaboration.
Tbe Repon is produced sirnultaneously in four hnguages (Englisb, Frencb, German and Spanisb) by tbe
IPN; to tbese one could add tbe ltal'ian translation wlunteered by ENEA: yet anotber sign of tbe Reportl
increasing ùihlity. Thefact that it is not only auaihble in seueral languages, but also largely prepared and
produced on tbe Internet World Wi.de Web, makes it quite an uncotnmon undenahing.
Ve sball continue to endeawur to find the best way of fulfilling tbe eqectations of our quite diuene
readasbip, awiding ouersinpfuation, as well as encyclopaedic reuiaas and the inaccessiAility of academic
joumab. The key is to remind ouneh.es, as well as tbe readen, tbat we cannot b all tbings to all pople, tbat
it is inportant to catue our nhbe and continue optimally @loring and qloiting it, bopng to illuminate
topics under a new, ranaling ligbt for the benefit of tbe readets, in order to prepare tbefi for nanaging tbe
cbalbnges ahead.
-J"T-J
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Pre/ace
boull like to ?evote thi'd iaduz of Tbe IPTS Rcport to bealth relate? itaua,
an area in wbitb cltanget in mnàern tocizty are botb poaing new cballenget
an? creating new opportunitiet The umztimzd perplexing ?euelopmznt of a
'beabb marlcet", or tbe aeriout concern ouer bovine encephal-opatby ('nn?
cow" ?itearc) raite new queiliont to phirb aruperd mu,tt be aougbt. Howeuey
?evelopmentt in telzmzàicine, mininturization of durgical technQued,
increa,ting li/e-expectanclt are alao milutonet on tbe way to a better
quafu rf l'/r.
Society t ?"y i, caught in tbe croufire between /ear an? progrett, laopu an?
worriu. Biotechnologry ltat ma?e buge acbicuemzntd, for eaample in protecting
cropt againtt paratite4 improve? contervation of foo?dtffi' new treatmznta
for?iaeau, an? do on. But mnny people are a/ra? tbat we are playing at being
tbe "dorcerer) apprentice", tbat we are going too far; witbout atopping to weigb
up tbe ritfu for our beabh an? environmznt. Scicnce an? retearch mutt
reqon? to tbeu concenu.
futween 1995 an? 2025 the num^ber o/ peoplz age? over 65 will inteau by 7o/0.
Naturally, tbe fad that we have been ablc to improve li/e-expectancy to ducb
an extent it goo? cauae/or datùfaùion. But, pill ee be ablz to a?apt our bealtb
tyttemt an7 mz?ital tecltnQuzd to mzet tbe dpect/ic nee?d of tbit population?
CEÉ.: XVIW
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we are able to proàuce goo?a better an7 more clteap$t, but pe dhoul7 take a lruaon
/rom tbe corueqtuncel of wbat bat been callc? tbe 'ma? cow affab". To wbat extent
?o we matter the ritkd? Once again, only dcience an? reuarcb can provàe ut tbe
arueeru to tbeu complex quutioru,
Tbe Commitdion it aware of the concernt o/ tbe European (Jnion7 citizent. Tbe
multi-/acete? nature of ?euelopmzntd in tbe li/e dciznced cAn eeen m"ake tbe notion o/
Progrerl itdel/ unclcan The Committion bat tbut ?ecàe? to give priorily to reuarclt
actiuitizd in tbe laealtb fielà. Tbe new Reuarcb an? Tecbnical Developmtnt
Framzwork Programmz dboul? ?evote a dpeci/it programmz to it. Tbù i^d a rational
an7 s,ell-tbougbt-out ?ecùion. ll/itb tlte fanta^dtic ?euel^opmzntt plaicb are taking
place before our eery eyed, we nee? to ftnow an? reauure, un?erttan? an? inform, an?
reconcilz ourtelyet wit/e tbe li/e dciencea.
-J'-J'J
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SPECIAL ISSUE: Health pollcy
Edltorlal
Brldelne thc O.p between the lntor6sts of Patlents and tho
Pharmac€utlcals Uarlet
Public backing for research into why different patienìs respond differently to the same
treatment, comparison between apparently equivalent drugs, treatments for so-called 'rare'
diseases and treatments aimed at poorer populations may have considerable benefits for both
patients and over-sùetched public health systems.
Early warnlng system and T€chnologles to Pt€Yent Footl-born€
DlsGases: Tho uS Experlenco
The increasing complexity of the chains of supply along which food moves from producers
to consumers makes new controls and monitoring and even stricter hygiene essential. New
food and organizational technologies will play an increasing role and the US experience can
offer insights.
European H€alth Pollcy: Deflnlng Prlorltl€s
For various reasons the European Union has tended not to involve iself in health-related
matters. Nevertheless, recent events have shown the need for coordination, and perhaps the
time has come to redefine priorities.
Telemsdlclnc: Fulfllllne the Promlse
Relatively poor uptake of telemedicine may be due to too much emphasis being placed on
the technologies and not enough on social and medical needs, together with the differences
in approach between the information technology and medical domains.
32 iitnlmally lnyaslu€ surgory: Ben€fltlng Patl€nts and Health'care
f systoms
Minimally invasive techniques offer the potential to reduce hospital stays and the physical
impact of operations on patients and thus limit the overall burden on health care systems.
However, deriving greatest benefit from new techniques and teaching the skills required to
exploit them, requires support be given to information dissemination, training and equipment
sTNETNoc
8ÉpilEIB,rn 1C9'
uEo wtilenFrÈÙrE Fo8 PRo6REGTVEj rEcHrgÈcÀ[§ruuE5{fl5,
ArÉ k§Jrd-hEoooel?tlon wltr
frre ErtiHr§TrùEén tury ttotuort
ÉuB.ISHED sy I}E B.RoPEAN cd,MISSPil
JomBfihcente
rsu: i@+s584
CabtosrE t{nlr P({A-97S-s{-c
DÉPOf GqAL SE-4957-95
DthEÈror
8oÙttiÉer
rst'ot*rcxrer
orlE*rwt*ou
EDITORIAL qOARD
K. B6e Hrbffi-tstul Flc{iffi9. c. carùj,
0. FalvedaoB J.6l$9an §ùled+dton
, ìHtr|dog/-Efiplryfifit{ompeÉlEwrEs9,
u. 6(à*:, tt. tku0nop §rb,€ct-EdtonÌ"rwo, D. (yftstqi GÈiilre Edltor ilrd gffi-
eom rronnawr'rd Hnrnur{cahn redtnologg,
r. Meghhos (Prodlctftn Uiracen, o. Pa@n€h0ou '
§&lect-Editon Erlrlolffn€rfl , A" soda l§.ddect-
ÉdEon EmrSLP. soflJp, C. Tahk
tBoB+rloN
cs{ooc-csrclct sÙrqs uN00bnc6
PIFIT
sÉd
tnAli§thnq.t
ry$§osuIsBIlcG
ÈffqH§ofll
ne*ÀoOreseA 5fib B.Èxcatb.r dorÉ
n@ rEnEd fiq Clle turopdr comr*don
O,ECSC-EEC+AE€ Bi$#tD(embo.r9. 1§É7
R€proddon b adEd+4 reptfor coflilrErdd
h{@, p(ordd tE srce ls a&}olilledg€d.
Ihe Ecmay rmbÉfid G§po{6*refdt,l6 lEÉ
trìad6of tiahffion
Trltlritltrort
b Blb{*'ed h tie ffi t.€k of èl,cry modt, ffipt
trtleFrcr{fEof Jt{ryardAlsust Èb6dted h
HC6fi d b q,rÈrtlY${frblèfrÉeddlrse, kt
falr H|g#: Enc*r Fharh, cemar dd wt.
:
auffirrflofl
For e froe §.ÈùcrliÉooF rhe lP,l§ REpùt, d to
drE É rn edsun0.§S§6blt.phewriE wthful
dsf;to:
'ItE Fl§ÈFitsec,eBrar
P'l§*Cseìila
urorul$ecerm
EbÉbcaÉe
F4r@$&.spdr
lH: +Stt*$88 28tI
Foc +3+$a4E 255
Éndr hf$,rE('*c€§
lrr€bdrcle lyuftìr,It,gsi$(5rEport/9.ÈÉ('be.terl
-J -J ,J -J -J
O IPTS - JRC - Sevrlle, 1997
6
7
12
r
l9
7
25
V
l7 Brl€f note: Enylronment and Health
The IPTS Report
EDITORIAL
Medlclne and Publlc Health In Europe in
the 21st Century
Georgios Mezelas and Dimitrios
Trichopoulos
n this issue of the IPTS Report, distinguished
authors contemplate the face of medicine and
public health in Europe in the next few
decades. They point out that market forces are
necessary but not sufficient to match the interests
of pharmaceutical industry with those of patients
at large; they examine how the ever larger scale of
food production and distribution has necessitated
the introduction of strict new standards and why
early warning systems and technologies need to
be developed in order to prevent food-borne
diseases from becoming major epidemics; they
consider the role of a European health policy, and
criteria for defining it. lts objectives and
limitations are considered and they demonstrate
how information technology in general and
telemedicine in particular can make scarce
expertise available to large numbers of health
professionals and patients; and they indicate that
minimally invasive surgery through laparoscopy
or endoscopy, could effectively address the
imbalance between demand for, and supply of,
surgical care. ln this brief introduction we offer
our vision of the health landscape in Europe, as it
is evolving under the influence of scientific
discoveries, technological developments and
multi-dimensional social transformations.
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We will consider, in turn: disease aetiology,
pathogenesis and diagnosis; disease treatment;
public health and health policies; and emerging
ethical issues.
With molecular biology research expanding
exponentially, and the human genome project
advancing rapidly, nature will be left with few
secrets about the structures and processes that
affect human health and disease. lmaging
technologies and molecular probes will vastly
facilitate and accelerate diagnostic efforts.
lmprovement in treatment effectiveness, however,
will be much more limited for at least two
reasons. Conection of molecular damage is a far
more complicated task than its recognition, and it
is very difficult to predict whether corrective
interventions will be risk-free. Moreover, we
already are at the stage of diminishing marginal
returns in our efforts to surgically treat
cardiovascular disease and cancer. This should
not be interpreted as indicating that progress will
be impossible or minimal. Optimism, however,
should be tempered by the recognition of limits
imposed by our own structural and functional
complexity.
It should also be recognized that in an ageing
population like that of Europe, striking medical
successes, for example effective treatment of half
of the currently untreatable forms of cancer, will
add no more than about one year to our life
-J'-J'J
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expectancy. Causes of death do compete, and
defeating one or more of them at the high-risk
field of advanced age has little effect on overall
survival. lt is in this context that prevention of
accidents should be a prioriry but we rarely think
of them in this way, particularly in the
Mediterranean belt of Europe.
Ethical issues arè likely to dominate health
policies in the coming century. Rationing of
health services may become explicit rather than
implicit, particularly when the battle is fought in
the over 80 years domain. Quality of life during
the terminal years and quality of death will be
dominant issues. Biology and technology may
guide medicine to unprecedented success, and
health policies may address equi§ issues more
effectively than at any time in the past. A higher
proportion of people than ever before will be able
to comfortably reach advanced age. lt will be a
daunting challenge to infuse as much happiness
as possible to the material comfort of these
people, who frequently will walk alone the last
path of their lives.
The IPTS Report
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ln a number of cases
there is a clear lack of
connection between
Patients' needs
and the goals of
pharmaceutical
research
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Bridging the Gap between the
lnterests of Patients and the
Pharmaceuticals Market
silvio carattini,,st,tuto dt Ricerche Farmacologlche "Marlo Negrl"
lntroductlon Examples
Rare Diseases
Diseases are intensively researched either
because they are frequent, such as cancer/ or
because they arouse strong emotions in the
population, such as AIDS or -often- because they
affect people who are well-known, eg. muscular
dystrophy. However, many diseases are not the
focus of significant research efforts lust because
they are rare.
It is difficult to define the term 'rare diseases',
which is used to describe an important but
neglected area of medicine. The only available
definition was proposed by the United States
Congress in the ORPHAN DRUC ACT. Under this
1983 laW whose aim was to encourage the
J'''J
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his article addresses the following basic
question: 'ls research on drug efficacy and
safety moving in the direction of the
patient's interests or do other factors
predominate, creating a gap between what is
being done and what is needed?'. Briefly the
answer is that in a number of cases, there is a
clear lack of connection between patients' needs
and the goals of pharmaceutical research.
The article gives examples illustrating the
problem and proposes some solutions. The
intention is not to make recriminations but simply
to set out the facts as they stand and the apparent
imbalances which are not addressed by the
current framework.
tcue nare. dhsasè6 ecctiunt for about 1016 of pathology dlstlbutsd h"aoor.rt s,m
swdromos; hundred of mllflons of patl€nB h developlng. countrles §titrGr troplcal
dlssasBs; vartablè pprcaribges of patlenB wlth common dleeases aro ,reSlstant to
- 
otherwlss successfut tfisrapl€s; fie maJortty d patlen§ sxposed to llfe-long drug
fiEatmenB do not bencflt bocause there ls lltde lfltèÌ€st ln s§tabllsblng crltorh to
ldenofy responshr€ paflents; and lt ]s often dtfflcuE to make a ratlonal s€hcugn among
drugs o'f ttrs ssfiE thdirpBrrflc class because of the lack of comparetlve s'urotes. mese so-
catta 'rhnan' §ltudons adwr§ely lmpact Fdents, who are dgprtv€d of potentlal
re#eotes, andrdlonal h68ltn 
:ystsms 
whlch oeàr1 an unnecE§sary fl nan*I burden,
ndbvàncè Thers are often dlscr€pancles be'tyvoen tfié noeds of som6 groups ot padonts
and gods oÉ pilurmaoeuflcal re6earch objecflv€s and the pflorlfle§ $tabllshed Dv
rÉuonal heffih systems wlthln the EU. A need may exlst for an agency d€allhg wlth ffi€3e
lssu€s ft Èufopoan lcvel.
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pharmaceutical industry to work on developing
drugs with little commercial value, a disease is
considered to be rare when it affects fewer than
200,000 US citizens. This explains why the term
'orphan disease' is often used in place of 'rare
disease' and makes the term 'orphan drug' self-
explanatory. On the basis of this definition, it can
be calculated that l0 to 20 million US citizens,
and probably the same or a larger number of
individuals in the European Union (EU), suffer
from any one of the 5,000 recognized rare
diseases. This accounts for approximately 10o/' of
all human pathological conditions.
Rare diseases can be hereditary or acquired,
congenital or appearing only in adult life.
Diseases like muscular dystrophy and multiple
sclerosis are familiar to the layman, whereas
others, like hemolytic-uremic syndrome and
osteogenesis imperfecta are not. Civen the wide
varie§, rare diseases fall into various fields of
medicine including neurology, haematology,
dermatology, orthopaed ics.
The costs of rare diseases are enormous not
only in terms of money but also in terms of human
suffering. Medical expenses for certain rare
disorders may amount to hundreds of thousands
of dollars per year. For instance, type I Caucher's
disease can now be treated using the missing
enzyme, aglucerase, now available in a pure
form. However, the cost of life-long treatment is
so high that aglucerase is known as 'the world's
most expensive drug'. ln terms of suffering, rare
disease patients' are often severely handicapped,
thus missing educational and employment
opportunities. These patients' family members
usually get very involved, both emotionally and
from a practical point of view.
Researchers, physicians and health authorities
all recognize that our knowledge is adequate on
the etio-pathogenesis of many rare diseases but
-J-J'-J-J
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that there is still too little experimental and
clinical research. Thus, the chances oftherapeutic
breakthroughs are negligible. In addition, even if
there is interest in research on orphan diseases,
scientists invariably face considerable
organizational difficulties. An investigation by the
U.S. National Commission on orphan diseases
found that 47o/o of the investigators interested in
rare pathologies had difficulty recruiting enough
patients for research projects; 75% of patients
reported difficulties in obtaining information
about research projects they might want to take
part in; 42o/o of practising physicians say they
need printed information for their patients but are
unable to find it.
The European scenario is no better. ln Europe,
the greatest obstacle to studies on rare diseases is
the lack of specific expertise. Consequently,
treatments are frequently inappropriate,
ineffective and sometimes even harmful. Anxious
families pay useless visits to doctors, hospitals and
healers, especially when a sick child is involved.
Even so, neither a systematic review nor an
orderly classification of rare diseases is available.
lndeed, many of these pathological entities have
not even been identified satisfactorily.
Examples of the variety of treatments used and
anecdotally reported to be effective could be
given for many rare diseases. There is a clear need
for randomized clinical trials (RCT) to validate
current therapeutic regimens and to establish the
value of new therapeutic approaches.
It is fair to say that rare disease patients suffer
a double discrimination: they do not receive
adequate medical attention and they have little
hope of effective therapeutic strategies ever
becoming available. The pharmaceutical industry
which, by definition pursues profit, is keen
enough to produce new drugs, even drugs of the
'me-too' variety, if the market is large enough.
The IPTS Report
'Rare diseases' are
often unfamiliar to the
layman and fall into a
wide varieW of
categories,
nevertheless they
account for 10% of all
pathological conditions
The costs of rare
diseases are enormous,
not only in terms of
money, but also in
terms of human
suffering
As might be expected
the pharmaceutical
industry is not
interested in producing
drugs for such a small
market
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Countries with a high
incidence of tropical
diseases are generally
too poor to pay for
drugs. Thus a billion
people remain without
protection against the
infectious diseases to
which they are exposed
Hypotensive effect
does not necessarily
translate into reduced
mortaliW or morbidiW
Predictably enough, they are not interested in
producing drugs for a small market. This makes it
impossible to assemble the substantial resources
necessary to discover and develop new drugs.
ltopical Dlseases
A similar situation is observed for diseases that
are widespread, but almost exclusively in less-
developed countries which lack the financial
resources to pay for effective therapeutic options.
Malaria, schistosomiasis, filariasis, trypanosomiasis
are just a few of the diseases affecting millions of
people for which remedies are still scarce, and
research aimed at finding new drugs is confined to
a handful of specialized centres.
Once again the lack of interest is backed by
economic reasons. The pharmaceutical industry
cannot afford research programs for this type of
patient. ln spite of the potentially large market,
the countries with a high incidence of tropical
diseases are generally too poor to pay for drugs,
no matter how low the price might be. Thus,
a billion people remain without protection
against the infectious diseases to which they
are exposed.
Programs to develop drugs against tropical
diseases, which are mainly supported by WHO
and by the US Army, are clearly insufficient and
under-funded and are unlikely to provide a real
answer to this awesome problem.
Druo Evaluatlon
There is little doubt nowadays that marketed
drugs undergo tougher scrutiny than in the past to
determine their safety and efficacy. However,
there are a number of distortions at various levels
and research in the patient's interest is sometimes
against the drug producers' interests. Again, I will
give a few examples.
No 17 September 1997
The potential market for a certain class of drugs
affects the amount of research done. For example,
patients with hypertension are the target of a large
number of basic and clinical studies. This is
because hypertension is very widespread so,
logically, the pharmaceutical industry's research
effort is proportional to the projected sales. The
remarkable number of potential consumers of
antihypertensive drugs has spurred companies not
only to spend large amounts of money developing
active compounds but also to investigate
thoroughly their mechanisms of pharmacological
action. As a result, at least six major classes of
antihypertensive drugs are known, i.e. diuretics, b-
adrenergic blockers, a-adrenergic antagonists,
inhibitors of angiotensin converting enzyme,
inhibitors of angiotensine receptors and calcium
antagonists. All these classes of compounds
certainly reduce blood pressure, but the
hypotensive effect does not necessarily
automatically translate into a therapeutic advantage
in terms of reduced mortality or morbidity. Studies
aimed at assessing effects on hard end-points like
mortality or morbidity are available only for a
minori§ of diuretics and b-adrenergic blockers.
Therefore hypertensive patients have the same
chances of receiving therapeutically active drugs as
of receiving treatments which, while lowering
blood pressure, have not been proved to have a real
impact in terms of survival. Thus recently
developed drugs with no proven impact on
mortali§ or morbidity are likely to be more
extensively prescribed than old drugs with
demonstrated efficacy. This is because new drugs
tend to be more expensive than older ones, so they
offer larger margins for promotion.
For any given disease there is always a small
proportion of patients who do not respond to drugs
that are effective on the rest of the population.
There are hypertensive patients who are difficult to
manage with today's drugs. By the same token,
,-J"-J
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there are subsets of depressed individuals who
do not benefit from antidepressant agents and
people with gastric ulcer who are not healed by
anti-ulcer drugs.
It would be interesting to clarify why there are
non-responsive patients and whether a patient
resistant to one drug is sensitive to other
compounds of the same therapeutic class.
Unfortunately, apart from anecdotal reports or
promotional claims, no systematic studies have
been made. Again, the interests of these subsets of
patients are not taken into consideration, because
they are less appealing to drug producers than the
majority of the population.
For each drug that is the prototype for the
therapy of any given disease or symptom, many
other congeners are developed. ln most cases,
compared to the prototypic compound, congeners
only have minor chemical modifications and offer
no major therapeutic advantages. These products
are justly known as 'me-too' drugs. For example,
there are about ten angiotensin-converting enzyme
inhibitors, more than 20 non-steroidal anti-
inflammmatory drugs and about 25 derivatives of
cephalosporin.
It would be desirable to establish how different
congeners compare in terms of efficacy, adverse
reaction profile and interchangeability.
Unfortunately data are generally not available and
controlled studies are designed only to establish the
so,called 'equivalence' of producs. ln most cases,
however, equivalence is not attained or
demonstrated and differences in efficacy reach 10-
20o/o, given the numbers of patients in most
'equivalence' trials.
Therefore, drugs with similar indications but
unknown relative therapeutic potency are
simultaneously available on the market. Drug
promotion campaigns can therefore heavily
-J -J -J -J .J
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influence physicians' prescriptions, so patients do
not necessarily get the best available treatment. ln
this case too, it is not in the industry's interest to do
serious comparative studies because the results
might eliminate the less effective drugs from the
market. Furthermore, if drugs belonging to the same
therapeutic class showed similar efficacy, price
differences would not be justified.
Some effective treatments, such as those based
on hypercholesteremic, antihypertensive and
platelet-anti-aggregating agents, must be
administered for many years sometimes throughout
life. Some of these drugs are quite expensive and
must be prescribed to many patients in order to
obtain benefits in only a small proportion of the
population. Thus, the majority of patients are
treated with no advantage, which dramatically
affecb the actual cost per life saved. For instance,
1,000 patients who have had a myocardial
infarction must be treated with aspirin for two years
to avoid 40 major adverse events (death or other
myocardial infarctions). Similarly, 1,000 cases must
be treated with simvastatin, a hypercholesteremic
agent, for about six years to avoid 33 deaths.
lf it were possible to design studies aimed at
predicting which individuals are most likely to
hnefit from a certain treatment, the number of
people exposed to the drug could be substantially
reduced. This would eventually lead to far fewer
adverse effects and to a reduction of the financial
burden. These studies, however, are unlikely to be
done. lndustry is interested in treating the largest
possible number of patients whereas national health
services would like to cover the costs of medication
only for those who benefit from treatment.
concluslon
For these different reasons many patients do not
receive optimal medical treatment. More
importantly, they have no hope of improvement in
The IPTS Report
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It is hoped that the 5th
Framework
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conjunction with other
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complement the
industry's drug
development and
direct more resources
towards meeting the
needs of patients and
health systems
the near future because there is too little research,
mainly because of economic reasons. lt is clear that
pharmaceutical companies cannot be forced into
research which is not profitable and goes against
the logic of marketing. However, it is reasonable to
require that new chemical entities designed after
lead compounds be tested for efficacy and side
effects relative to the prototype drug.
These questions concern not only individual
patienb but the whole communiry since health
expenses are frequently covered by national health
systems. The lack of therapies for rare diseases and
for non-responsive patients pose an additional
financial burden on national health systems.
lmportant resources could be spared if sound
comparative studies were made of drugs of the
same therapeutic class, as this would permit the
selection of the least expensive option. Finally,
identifying the subsets of patients benefiting from
chronic treatment would expose fewer people to
useless drugs, with a proportional decrease in
expenses for national health systems.
Unfortunately, we are unlikely to see any
improvement if society continues to delegate drug
development and evaluation almost entirely to the
pharmaceutical industry. This is not meant to
undenate the significant conùibutions industry has
made to human health. The pharmaceutical
industry however, needs continuous incentivation
in its efforts to produce new drugs. The time has
come to recognize that industry alone cannot cope
with all the needs of patients, and that sometimes its
interests conflict with those of national health
systems. Thus, more space must be allocated to
research into questions of public interest.
Recommendafions
To cope with the above needs, an entity could
be established whose mission would be to highlight
problems and priorities. This entity would be a
No 17 September 1997
totally independent body distinct from the one for
approval of new drugs (EMEA), must be able to
finance research in the name of public interest. lt
would obviously be wasteful if each European
country were to implement such a program
separately. Although some local problems may
require specific solutions, most are common to all
European countries, so it is justified to propose a
loint effort.
There is, of course, already a Biomed program of
the EU which could take on the task. However, it
may be suggested that:
a) biomed collects answers to the researchers
questions but, up to now, it has not been able to
propose specific topics of interest;
b) the kind of studies proposed here require
resources which are an order of magnitude larger
than those available today.
The 5th framework program of the EU might
offer a great opportuni§ to direct biomedical
research towards the needs of patients and national
health systems, with the aim of complementing
industrial research programs. The following points
illustrate potential areas of priority.
l. Rare diseases. ln vitro and in vivo models are
needed for rare diseases. New opportunities offered
by cellular and molecular biology techniques can
be exploited. Tissue culture, particularly using cells
from transgenic and 'knock-out' mice, is an
excellent way of testing the beneficial effecs of
chemical compounds. The EU counnies may pool
their financial resources to avoid duplication. This is
an area where collaborative efforts are needed, as
no single research group has all the necessary
know-how and facilities to cope with the complex
process of transforming ideas into marketable drugs.
A European Network of Clinical Trials (ENTC) on
rare diseases needs to be set up, with the
collaboration ofexisting centres. There is no need to
stress this point because any effort by a single
,,-JT-J
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country is bound to fall short, given the rarity of
these patients. Collaboration on the European scale
is absolutely essential to recruit enough patients to
obtain statistically significant results in a short time.
A program to help patients with rare diseases
should include an information centre open to
physicians and to the general public. These centres
should provide the means of tracking down patients
with specific rare diseases, by keeping specialized
registries available to interested investigators. The
centres should also act as repositories for orphan
drugs, particularly those not yet available on the
market. Epidemiological studies and investigations
on the natural history of rare diseases could be
usefully coordinated by these centres.
2. Tropical diseases. Existing programs need to
be upgraded, such as the WHO TDR [Iropical
Disease Research) in order to expand research for
drugs for diseases such as malaria, schistosomiasis,
trypanosomiasis and filariasis. ln vitro and in vivo
tests exist but they could be improved, and more
highly specialized centres are needed to do this. We
need better knowledge of the physiology of parasites
and must test a larger number of chemicals. The
creation of better health infrastructures so that
clinical trials could be organized properly in
developing countries, where patients are available,
is a difficult task, but has high priority.
3. Drus evaluation. Existing drugs, particularly
those for chronic and severe diseases, need to be
evaluated better. lf a drug is to be taken life-long, the
one's offering the greatest beneficial effects and most
favourable profile of adverse effects must be
selected. Thus, comparative studies are need.
Usually these require large numbers of patients, long
time-frames and cooperative groups with a suitable
organization framework. Drugs of the same class
should be compared on hard rather than surrogate
end-points. Pharmaco'economic evaluations should
be conducted within the framework of clinical trials,
as these are bound to give national health systems
important indications about costs and benefis.
Controlled trials are needed to sort out which
patients really benefit from chronic treatments.
Hypocholesteremic and anti-aggregating agents are
potential candidates for this type of trial. These
could spare over 90% of patients from ineffective
treatrnent and would greatly reduce the financial
burden on national health systems. f
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Early Warning System and
Technologies to Prevent Food-borne
Diseas€s: The US Experience
Robin Yeaton Woo, Kristin Digiulio, Lester Crawford,
oeorgetown universlty center for Foocl ancl Nutrltlon Pollcy
lntroductlon priority on research, which is supported by the
Breatest budget allocation. Notable emphasis has
been placed on prevention through enhanced
Hazard Analysis and Critical Control Point
(HACCP) measures, increased research and
development of detection and diagnostic kits, a
national early warning system that could isolate
incidents and sources of infection, and publiC
education. The public-private effort will provide
auxiliary funding to establish an effective food
safe§ campaign, an example of the trend towards
innovative partnerships utilizing private funds and
expertise for the common good. Finally, the
proposal calls for increased coordination among
the many local, state and federal agencies
responsible for food safety, but falls short of
creating one comprehensive agency. A single food
regulatory agency may seem the logical and most
efficient approach, but political realities in the US
-J"'-J
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iven the importance of food safe§, the US
recently promised to commit US $43.2
million to enhance food safety
proSrammes, including a national early
warning system for food-borne illness, improved
seafood-safety inspection, and expanded food
safety research, risk assessment, training and
educationl. The responsible agencies -Health and
Human Services, Agriculture, and Environmental
Protection- were given three months to develop a
strategic plan and submit a report outlining how
best to improve food safe§.
The strategic plan that was announced May 12,
1997, focuses on the five major points presented in
Box 1 Most important is the financial commitment
to make the plan work. The initiative places high
F
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make it a virtual impossibiliry although this does
not rule out the viability of a single-agency
approach in Europe,
HACCP
The Hazard Analysis and Critical Control Point
(HACCP) system is an integrated, preventative
approach that looks at the entire process that
brings food to the consumer. Developed in the
1960s by Pillsbury for NASA to ensure the safe§
of foods on manned space missions, HACCP
offers a comprehensive and scientific approach to
food safety.
lncreased use of HACCP has facilitated
harmonization of international food safety
regulations (e.g. the United Nation's Codex
Box 1. I{ew tlS Flve Polnt Plan
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Risk assessment
includes qualitative
analysis of the hazard
and quantitative risk
management
Alimentarius Commission has endorsed HACCP
as a regulatory tool). ln the US, the Food Safety
and lnspection Service (FSIS) published a final
rule in July 1995 establishing the use of HACCP in
USDA-inspected facilities.
HACCP is particularly suited for dealing with
microbiological contamination because it
emphasizes prevention, not just detection, of
contamination at all points along the chain. lt is a
decentralized approach where the focus is not on
micro-management by regulatory authorities, but
on all players in the food chain, making the end
product as safe as possible.
A comprehensive HACCP approach relies on
safeguards from the farm all the way to the
consumer's table. A plant must conduct an
analysis of its production process to determine
where there are potential risks to food safety and to
identify critical control points (CCPs). At CCPs,
controls, such as adequate chilling or food handler
hygiene, can be applied to decrease risk. Stringent
monitoring of CCPs and detailed records are vital.
As the road from producer to consumer
becomes longer and more convoluted, a systems
approach like HACCP becomes critical. After
leaving the processor, food is still vulnerable to
contamination. ln September 1994, for instance,
Salmonella infected an estimated 224,000 US
citizens nation-wide. Subsequent investigation
showed that the culprit was an ice cream pre-mix
transporter, an improperly sanitized truck
previously used to haul unpasteurized liquid eggs.
Contaminated ice cream was then distributed
throughout 48 states.
A recent outbreak of hepatitis from Mexican
strawberries demonstrates the added food safe§
vulnerability posed by international movement of
foodstuffs. Although it is not yet clear where the
contamination by Hepatitis A occurred, the
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disease has been spread to sites throughout the
western US. This incident has raised the question
of mandatory country-of-origin labelling for food
products. Members of the US House of
Representatives Agriculture Committee are
cunently considering proposing this option, but it
is sure to be a contentious issue.
As food safety is a farm{o-fork endeavour,
education of food handlers, both at public
establishments and at home, will aid in reducing
food-borne illness. Recently, the US Department
of Agriculture (USDA) mandated food handling
labels on meat products to provide information on
proper storing and cooking temperatures. A meat
and poultry hot-line is available to address
consumer concerns about proper handling and
storage. The USDA's Cooperative Extension
System is establishing public and private
partnerships to develop innovative education
programs that will change food handling
behaviours.
While measures to prevent and control food-
borne illnesses can be taken, the resources to do
so are not limitless. The extent of the associated
risk must be evaluated, for example, with specific
products, disease organisms, or susceptible
human sub-populations to prioritize efforts.
Accordingly, the new US plan calls for increased
use of improved risk assessment methods. The
World Trade Organization's Agreement on
Sanitary and Phytosanitary Measures requires risk
assessment as part of their safety protocol. The
risk assessment process consists of a qualitative
analysis of the hazard, followed by a quantitative
risk management approach. Risk assessment
frameworks have traditionally been used for
chemical hazards, but the unique nature of
microbial contamination calls for new methods to
better characterize and quantify potential risks.
Predictive microbiological models have been
developed by, among others, the Agriculture
J.JJ.J'
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Research Service of USDA and the UK's Ministry
of Agriculture, Fisheries and Food. These
quantitative models, which are still being refined,
provide valuable information in identifying CCPs
and developing a working HACCP plan.
Early warnlng §'ystem: The sentlnel sltes
Food-borne diseases in the US and elsewhere
historically have been reported on a passive basis.
The US Centers for Disease Control and
Prevention (CDC) have relied on state and local
health authorities to report cases of disease. ln fact,
an estimated 95% of sporadic cases go unreported.
Comprehensive surveillance would require a
chain of increased awareness beginning with:
(1) realization by infected victims that their illness
may be due to something they ate and that it is
important to see
(2) a physician who, upon verifying the nature of
the illness to be food+elated, would report the
incident to
(3) a local public health authority, who would
investigate the origin of the incident, identify
related cases, and report to
(4) the CDC and a world network system.
Measures to prevent further infection by the
source would be implemented at each step along
the way. Unfortunately, this idealized system can
break down early on in the chain.
ln the US approach an active surveillance
system, where public health authorities
systematically solicit information on food-borne
disease cases, can identify risks to public health
posed by food-borne pathogens. lnquiries would
be made of physicians by local health officials,
and of local health agencies by the state, and of
the states by CDC. This system would generate
more accurate numbers for risk analysis, for
instance of the number of people in different age
groups affected by particular pathogens, the
-J-J.J'-J
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frequency of particular modes of infection, and
the relative vulnerability of different food stuffs
to contamination.
ln '1995, USDAs Food Safety and lnspection
Service, the US Food and Drug Administration and
CDC collaborated to create a new surveillance
program, the Sentinel Site Study, now known as
FoodNet. This programme uses active surveillance
to enhance data collection and establish baseline
levels of food-borne disease incidence in the US.
Most importantly, this programme reveals how
best to establish a network responsive to new
outbreaks and emerging diseases.
Active surveillance for food-related illness was
initiated in five selected sites: northern California,
Oregon, Connecticut, and the Breater
metropolitan areas of Minneapolis§t. Paul and
Atlanta. ln 1997, surveillance expanded to New
York and Maryland, and an additional site will be
added soon. Seven pathogens have been targeted
as being of special concern: Campylobacter, E.
coli 0157:H7, Listeria, Salmonella, Shigella,
Vibrio and Yersinia. 1996, 7,259 laboratory-
confirmed diarrhoea cases were attributable to
these seven pathogens.
To coordinate data and develop predictive
models, three simultaneous surveys are being
conducted. A laboratory survey will determine
adequacy of testing for food-borne pathogens. The
physician survey will measure frequency of
referral of patients for laboratory analysis of
diarrhoea symptoms. The third survey will
determine the eating and health care behaviours of
adult and paediatric populations. Case-control
studies have also been initiated to study patient
behaviour prior to infection.
This programme has already been effective in
implicating raspberries as the vector in an 1996
outbreak of Cyclospora in California. Five
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Covernment funding
of research on new
diagnostics could
dramatically speed up
their availabiliW
additional outbreaks in 1996 were identified and
aftributed to specific food vectors. Campylobacter
was most frequently isolated from patients,
followed in order by Salmonella, Shigella and E.
coli 0157:H7.
It is vital to enhance system effectiveness by
incorporating new technologies as they are
developed through basic research. For instance,
new funds allocated for the programme will allow
the development of a bacterial DNA fingerprint
database. This will enable food safe§ experts to
match the patient sample and suspect foods to
identify the source of food contamination by
genetic identification of the specific culprit
pathogen, even if the source is remote from the
incident. ln the future, advances In genetic
research may give this system the power to
identify genes conferring bacterial resistance to
anti-microbials, thus facilitating treatment as well
as detection.
Research and development of new
technologles
Research to develop quick, reliable, and
affordable methods of detecting low levels of
pathogens is essential. At present, no such system
exists for the identification of Hepatitis A or
Cyclospora; and many of the tests we do have are
prohibitively expensive, unwieldy, or take too
long. A fast, easy test for specific pathogens or
indicator organisms would allow frequent, simple
in-plant safety checks and could greatly improve
the HACCP plan. ln the US approach it is hoped
that funding of research and development of these
new diagnostics will dramatically speed up their
availability over the next few years.
Research in microbial genetics will provide
answers to how pathogens become resistant to
traditional food preservation techniques such as
heat and refrigeration, and genetic engineering of
No 17 September 1997
foods may provide new control strategies. Other
physical control methods such as irradiation may
be employed as well.
When the concept of food irradiation was first
advocated by food safe§ experts, it met fierce
opposition from both the public in both Europe
and the US who feared ill effects from nuclear
radioactivity. As with cooking, marinating or
freeze-drying, food irradiation may cause slight
changes in the biochemical constituency of foods.
Thus, US federal law requires approval of the
irradiation process as a 'food additive,' and
irradiated products must be labelled as such.
The World Health Organization (WHO) has
carefully and thoroughly studied all aspects of
food irradiation for many years and has
consistently found virtually no risk, coupled with
impressive effectiveness. The WHO advocates the
use of irradiation not only for food safe§, but for
food preservation. ln so doing WHO has taken
note that approximately one-third of the world's
food supply spoils before it can be consumed.
While it cannot replace proper food handling as
the single most critical food safety measure,
irradiation provides many benefits that we believe
could solve some of the problems caused by food-
borne pathogens (Table 2).
Despite regulatory approval, irradiation is not
commonly used in the US because food purveyors
and processors, unwilling to challenge consumer
confidence, have bowed to pressures from activist
groups seeking to prevent its use. There are also
some unanswered questions about the long{erm
effectiveness of irradiation, and what effects re-
irradiation might have on food safety and
extended shelf life. Actual market tests show that
consumers would purchase irradiated foods if
educated about the benefits and safety of the
irradiation process. Civen the current problems in
food safety, we feel that allocating funds to study
T-J-J"
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Box 2. Adyantages of Food lrradlatlon
The IPTS Report
Food purveyors tend
to bow to consumer
apprehension, and
questions remain about
the long-term
effectiveness of
irradiation and the
effects of re-irradiation
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* Bacterial and fungal support and viruses are not affected by the most
irradiation
Source Food Control , Vol, 7. No 2
re-irradiation and to improve awareness about
irradiation would be effective in decreasing
purveyor and consumer apprehension.
Global lmpact
The US plans to develop additional mutual
recognition agreements with its trading partners to
ensure that imported foods are produced and
manufactured under systems that offer comparable
safety measures. The new funds provided by the
new US food safety initiative will also provide
technical assistance to foreign countries on safe
growing and handling practices. Use of the HACCP
system would be one way to ease regulatory
harmonization across countries, as it facilitates
establishment of 'equivalence' in safety measures.
Concluslons
We have reviewed here the recent US
reaction to the increasing perils of food-borne
-J-J-J'-J
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illness -involving a comprehensive and
adequately-funded strategic plan. Europe has
the expertise to develop a strategy to deal
with these issues.
Based on the US experience we would
emphasize that basic research is the essential first
step in any effective programme for ensuring food
safe§, characterized by the following principal
components:
' 
funding for basic research and development of
diagnostics and microbial conhol methods
' 
incorporation of state-of-the-art science and
technology in a farm-to-fork approach
' 
involvement and increased awareness of
health professionals and veterinarians to
identify
' 
cases early in the chain of events
' 
education of consumers and commercial food
handlers
' 
active surveillance facilitating an early
warning system. f
commonly used doses levels of
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European Health Policy: Defining
Priorities
Elias Mossialos, fhe ISE
htroductlon
he EU Member States' relative reluctance
to further develop a European health policy
framework may be because of the primary
emphasis on economic issues in building the
European Union. This may explain why health
often comes onto the policy agenda only in specific
relation to the needs of the Single Market, e.g. in
areas such as product safery health and safety at
work, pharmaceuticals and medical devices
and the free movement of professionals (McKee,
et al, 1996).
The lack of coordination between policies,
activities and programmes has been emphasized by
several researchers and commentators as well as
the public health community. There have been
voices in support of the development of a
Directorate Ceneral (DC) for Health since the early
1970s but nothing has come of this. The new
-J-J"-J
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institutional and legal framework introduced by the
Trea§ establishing the European Union in 1991
raised hopes that new policy developments were to
be introduced.
This paper reviews the legal framework within
which the European Union may act in the field of
health policy. lt then describes the current European
Commission's public health priorities and suggests
a methodological framework for prioris sefting in
European public health policy. Finally the need for
institutional changes is examined and a number of
recommendations are examined and discussed.
Current Eunop€an Commlsslon's Publlc
Health Prlorltles
The legal franrework has evolved consistently
since the founding of the Communis in 1956,
when its health concerns were limited to those
related to occupational health in the coal and steel
The IPTS Report
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Until the 1991 Treaty
on European Union
little attention was
paid to health at
European level
The Commission has
developed policies and
is funding research
programmes in
certain key health-
related areas
industries. The precedent in this initiative was that
a small proportion of the sales of those products
was used for research in public health protection.
The most significant provision in the field of
health was introduced in the 1991 Trea§ on
European Union. The Treaty gave new competence
in public health with the introduction of Articles
3(o) and 129.
Article 3(o) stipulates that the Communi§
should contribute to the attainment of a high level
of health protection. Article 129 identifies two areas
for Community action: disease prevention and
health protection. There are three means through
which these objectives can be achieved: research,
health information and education, and the
incorporation of health protection requirements in
the Community's other policies. However,
harmonization of the laws and regulations of the
Member States are specifically excluded.
ln addition, Article 129 is not entirely clear
concerning the responsibility of the Member States
and the Commission in terms of achieving its
objectives and in policy implementation. The
obligation of achieving a high level of human
health protection is laid upon the Communi§ as a
whole. The Community is also responsible for
directing actions towards the prevention of
diseases, in particular the major health scourges. lt
is not clear, however, what the major health
scourges are, although the one mentioned, drug
dependence, may from some points of view be
considered to be neither primarily a health matter
nor a scourSe.
Pursuant to the provisions of Articles 3(o) and
129, the Commission defined eight priori§ areas for
European Community action, following a long
process of consultation and negotiation, on
proposals made by the Commission, between the
various EU institutions, Member States, and other
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interested groups. These areas are drug
dependence, cancer, AIDS and other
communicable diseases, health monitoring,
injuries, pollution related diseases, and rare
diseases. ln addition, emphasis is placed on the
dissemination of information and evaluation of
those policies which are most effective (EC
Resolution, 1993). h is not easy to establish these
priorities and satisfy all the demands for action, but
we do at least have a list of priorities on which to
improve public health policy, or even to develop a
comprehensive health pol icy.
The Commission has already developed policies
in such fields as AIDS and communicable diseases,
cancer, tobacco, drug dependence, health
monitoring, the environment and health and safety
at work.
Research programmes already exist directed at
nutrition, cardiovascular diseases, mental illness
and the problems associated with ageing. The
Commission is now preparing draft
communications and proposals for European
Parl iament-Counci I decisions concerning five year
programmes of actions on rare diseases, pollution-
related diseases and the prevention of injuries. lt
has also prepared drafu -with a view to adoption in
1997- of communications and proposals for
European Parliament Council instruments
concerning safe§ and self-sufficiency of blood. The
development of methodologies and capacity for the
evaluation of health and health-related programmes
and measures is foreseen by the health monitoring
programme and preparatory work has already been
carried out with representatives of Member States.
Establlshlng Prlorltles at Eu Leuel:
A Methodologlcal Framoworl
Under the principle of subsidiarity and in light
of the limitations of Article 129 and the general
character of Article 3(o) of the Trea§ of the
-J-J-JT'
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European Union, the development of all-
embracing health policies is the responsibility of
each EU Member State as each one is faced with
a unique paftern of circumstances and challenges
to the health of its population. This diversity is
partly a result of differences in the complex
interplay of government policies and consumer
preferences as they affect factors such as tobacco,
alcohol, diet, and transport as well as biological
and environmental factors. However, precisely
because of the existence of differences, there is
significant scope for Member States to learn from
each others'experience as they develop their own
policies. There are also many areas in the field of
health promotion and disease prevention where
European Community policies have an important
role, ranging from agricultural policy and tax
harmonization to safety legislation. Some of these
problems as well as efforts to integrate health into
other Communi§ policies are described in two
reports already published by the Commission (EC
Report on Integration of Health Protection, 1996
and 1995). The integration of public health in
other Community policies was also raised in the
Commission's Creen Paper on 'Commercial
Communications in the lnternal Market'
(EC,1996) which deals with reducing barriers to
the free movement of goods and services between
Member States, in order to promote more efficient
marketing of commodities, and thereby make
available to EU citizens more goods at lesser cost.
The criteria that could be used to define European
Community functions are presented in Box l.
Areas for Community-wide policy
developments could include communicable
disease surveillance, the free movement of people
and goods including medicines and medical
devices, the collection of comparative data, the
standardization of definitions, health technology
assessment, environmental health policies,
and exchanging information on best practice
in health care.
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Following the Alma Ata declaration of 1978,
the World Health Organization developed a series
of targets known as the 'Health for All' targets.
These set out in general terms a series of
objectives and means of achieving them,
designed to be used by nation states in Eastern as
well as Western Europe. The task for the future
could be to examine how they can be adapted for
use in the European Union to provide an input to
the investment of resources in health and health
services, based on priorities of a variety of
conditions and services, so as to maximize the
improvement obtained in the health status of the
population. However, numerical targets have a
number of significant problems (Abel-Smith, et al,
1995). First, they can lead to artificial priority for
that which is measurable. Second, if taken in
isolation, they can represent an over-simplistic
description of policy. Third, unless the target
levels are carefully chosen, they can appear either
unrealistic and thus be dismissed as unattainable,
or simply a continuation of existing trends,
requiring no additional action to achieve them.
Despite a number of problems, targets could
be developed to provide a tangible means of
monitoring progress and act as a stimulus for the
collection of good quality data. They can also
highlight important areas of strategy and help in
the process of converting policy into programmes.
The specific identification of goals for
improvements in the population's health is a
prerequisite for the development of a strategic
approach to public health policy. lt is necessary to
identify intermediate objectives, not only for
health, but also for the important determinants of
health and the processes which lead to changes in
those factors. lnterventions are often better aimed
at individual determinants rather than specific
outcomes. This is important since health
outcomes display a complex relationship to
multiple causes or factors.
The IPTS Report
u
o
o,
6
4o'?t'
o.
One task is to examine r'
how the WHO targets
set by the Alma Ata
declaration may be
adapted to the needs
of both Eastern and
Western Europe
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To date the
Community's role has
been based on a
limited deFinition of
public health, restricted
to specific areas such
as'prevention','major
health scourges', and
'drug dependence'
More focus needs to
be placed on risks,
calling for a multi-
sectoral approach
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Priorities for health policy should, be
determined using five criteriai
. the extent and seriousness of the problem,
' 
whether effective preventive or curative
methods are available,
. whether rehabilitation is possible,
. whether such methods can be used
appropriately and efficiently,
. whether it can be left to individual
responsibility.
To date the Community's role has been based
on a limited definition of public health, restricted
to specific areas such as 'prevention', 'major
health scourges', and 'drug dependence'. This
was inevitable given the limited scope for public
health developments outlined in Article 129 of the
Treaty. While a disease based strategy may prove
politically successful such an approach has
reduced the Community's ability to make a
substantial contribution to the health of the
European citizens (Belcher and Mossialos, 1997).
Rather than this disease-based strategy, we
need greater focus on risk factors associated with
diseases and determinants of health. This calls for
a multi-sectoral approach that incorporates
subjects such as poverty, unemployment,
agriculture, transport, housing, and education.
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It is, therefore, very important to identify risks
which are associated with particular causes of
diseases. ldentification of risk rather than disease
does help in that some risks - eg. smoking
cigareftes, alcohol consumption, blood pressure
are associated with more than one disease. lt is
easier to convince people to tackle smoking as this
will have an effect on cancer of the lung, chronic
respiratory disease and ischaemic heart disease.
Priorities based on the burden of disease,
which is the direction of Article 129, may hide the
importance of attaching the risk factors of
relevance. ln addition, by identifying risk factors it
is clear that action is taken to implement a public
health policy involves more than the health service
- eg. education, agriculture, ransport and housing
(Holland, Mossialos, et al, 1998). Priorities for
action could include the following areas:
Smoking; alcohol-related harm; drug and
substance abuse; nutrition; exercise; mental health;
the physical and social environment; accidents and
injuries; occupational safety and health; family
planning; maternal and infant death; blood pressure
control; screening for cancer; dental health;
physical and sensory disability and surveillance and
control of infectious diseases (including sexually
transmitted diseases, HIV infection, etc.).
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Priorities for public health should, ideally, be
based on knowledge of the occurrence, socio-
economic consequences and preventability of
health problems, taking into account prediction of
future trends and the expected costs and benefits of
the public health measures.
The precise ranking of priorities in any area will
be largely determined by local circumstances,
availability of facilities, ability to mobilize effective
inter-agency activi§, as well as wishes of the
population.
It is argued that any action at Community level
should fit the 'added value' criteria which are the
most quoted determinant for EU activity. This is
intended to guide Community action, but there is
little understanding of what it actually means in
practice. Civen the differences between Member
States in the development of their public health
policies, health systems and socio.economic status,
what constitutes 'added value' is highly unlikely to
be the same for all Memhr States. The 'added
value' principle should reflect the different levels of
policy and institutional evolution of the Member
States, the development of human resources and
services and public health needs. Within this
context, knowledge transfer based on best practice
available among Member States and adapted to the
local environment should be a priori§, indeed a
target. Human resources development is another.
Current initiatives under the Fourth Framework
Research Programme support the mobility of
doctoral, post-doctoral and experienced researchers
between Member States, but is important that the
Commission also support local developments and
training and research centres in the Member States.
concluslon and nacommendatlons
' lt is now expected that a revision of Article 1 29
at the lntergovernmental Conference (lCC) will
influence further developnrents in the field of
-Jt-J-Jt
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European health policy. However, implementing a
new legal framework for setting priorities must go
hand in hand with reforms of European
Community institutions and decision-making.
Currently, health related activities are scattered
throughout the European Commission without
any effective central focus for health. This was
obvious in the BSE crisis, in which agriculture and
not health officials took the lead both in the
Commission and the Council of Ministers. Health
related problems are also discussed by ministers
of transport and industry at European level, for
example, but omitted from the agenda of meetings
of health ministers. This is not altogether a bad
practice as it enhances a multisectoral approach,
but there is currently no effective mechanism to
bring together all health-related discussions
(Holland, Mossialos, et al, 1998).
It is worth noting that thirteen of the
Directorates Ceneral (DCs) of the Commission
headed by different Commissioners are involved
in shaping health-related policies. ln the work of
a number of other Directorate Cenerals' general
health issues play an important indirect or direct
role (eg. Common Agricultural Policy, VAT
policy etc.).
It is worth. exploring the possibility of re-
organizing the responsibilities on health-related
matters at Community level particularly inside the
Commission. This has indeed also been voiced by
the European Parliament. Positive initiatives have
been taken by the European Commission and
President Jacques Santer to improve coordination
of policy formation and implementation. These
initiatives can be further enhanced by the
establishment of a new entity within the
Commission to coordinate currently scattered
activities and programmes. The discussions at
the recent lntergovernmental Conference
in Amsterdam make the outlook for this
seem positive.
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The 'added value'
principle may in
practice be difficult to
apply given that it is
unlikely to be the same
for all member states
The lack of a central
point for the discussion
of health-related issues
in the EC encourages a
multi-sectoral approach
but can reduce the
effectiveness of action
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A new entity could also develop -in
collaboration with the WHO and other
international organizations- common standards
and definitions so that comparative studies can be
undertaken to assess possible variations in health
needs, utilization, health expenditure and
outcome. A significant development will be the
establishment of a European-wide system of
surveillance of the incidence of communicable
diseases in order to identify new problems as they
arise and identify cases of changes in incidence.
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This is a field where considerable progress has
been made. Co-operative arrangements for the
evaluation of methods of treatment and
technology assessment would also be desirable.
Finally it should support research projects to
investigate the aetiology of some of the major
causes of mortality and morbidity in order to
identify possible preventive strateSies and sponsor
appropriate experiments to evaluate different
approaches to the control of diseases for which
preventive measures are known. f
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Telemedicin€: Fulfilling the promise
Jeremy Holland, The CEST
What ls Telem€dlclne This is conventionally interpreted as the use of
image and video transfer technology to enable a
remote specialist to see the same information that
a local physician is seeing. This form of
telemedicine has been researched since the 1970s.
However, the focus on one particular mode of
technology is one of the problems which has
frustrated progress in the sector. Consequently, the
author recommends that the broadest technical
interpretation be used, namely the use of
telecommunications to deliver health care.
Why all the fus§?
The health sector consumes between 6 and
8% of major European member state CDPs. This
is more than education or defence. Not only is the
health sector a large drain on national economies,
but it continues to Brow as a percentage of CDP.
he term 'Telemedicine' can be taken as
referring to a broad spectrum of activities
within health-care delivery. Taken literally,
it is the application of telecommunications
technology to the delivery of health care. This can
range from a CP making a telephone call to a
patient to sharing real-time Computed
Tomography (CT) scans between consultants in
hospitals in different continents. Some examples
of different telemedicine technology modes are
given in the table in box 1.
Perhaps the most succinct definition is "the
investigation, monitoring and management of
patients, and the education of patients and staff
using systems which allow ready access to expert
advice, no matter where the patient is located".
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Telemedicine is basically
the application of
telecommunications
technology to the
delivery of health care
and includes a variety
of techniques
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Telemedicine has the
potentialto make more
efficient use of medical
stafF, which represent
the greatest cost in
health care systems
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Box f . itodalltles of Telemedlclne
Consequently, any means of reducing health care
expenditure while maintaining the quality of care
is eagerly sought.
Direct operational staff costs make up by far
the largest proportion of the total health care
budget (in some countries over 80%). Any saving
in operational staff costs will therefore have a
major impact on costs. lt is because of its potential
to significantly improve the efficiency of use of
operational staff that Telemedicine has had such
an enthusiastic reception.
Health care is at heart a relatively simple
process: it is the efficient provision of the
appropriate medical expertise to the patient at the
earliest time possible. Of course, drugs,
equipment, and hospitals all feature heavily, but
health care is essentially a professional service.
But the geographical diversity of the community
and health services means that this relatively
simple process is extremely difficult to deliver
optimally. Patients may be difficult to access,
specialist expegise may be located far from the
need, or conversely a given source of expertise
may not be required by the local populace
(leading to expensive and disruptive relocation).
Telemedicine enables expertise to be provided to
a patient irrespective of its geographical location.
This holds out the prospect for massive
improvements in efficiency.
A number of scenarios have been described
which indicate some of the situations in which
telemedicine might be beneficial.
These include:
o Centralized pathology: the use of telecoms to
enable one expert pathologist to provide a
consultation service to several local hospitals
(in a ciW, for example) leading to more
-J"-J.J
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efficient use of resources at off-peak times
(such as at night). This scenario can be easily
translated to other specialisms.
o Rural service provision: the use of telecoms to
enable one specialist physician to provide near
simultaneous expertise to several remote rural
facilities that would be time-consuming and
expensive to visit physically.
o Devolution of care: the use of telecoms to
enable the provision of secondary care
expertise (i.e. a hospital consultant) at the
primary care interface (e.9. the CP's surgery)
where service is both cheaper and more
convenient for patients.
o Health care in 'strange places': the use of
telecoms to enable the provision of specialist
expertise to locations that have been isolated
from ready access to required levels of health
care knowledge. Examples include boats
(ferries, liners, and yachts), aircraft, the
battlefield, crash sites, and so on.
o Health care export: the use of telecoms to
expoft specialist expertise to other countries
with lower levels of health expertise. Several
organizations have attempted to make money
this way, although no significant successes
have been noted to date.
. Remote monitoring: the use of telecoms to
monitor a patient's condition or behaviour
from a centralized facility. This is a part of the
larger 'telehealth' concept. To date, remote
monitoring has been the most commercially
successfu I telemedical sector.
Of the scenarios given above, the major
benefits to the EU can be split into two areas:
health benefits and rural cohesion benefits.
Clearly, the more cost-effective delivery of service
will enable more of that service to be provided at
current levels of health care expenditures:
improving health outcomes at a fixed cost.
Equally significant is the benefit given to
rural communities.
,,J -J 
"O IPTS - JRC - Seville, 1997
Rural communities often suffer poorer health
than their urban counterparts, they have unique
requirements based on the ageing population, the
nature of employment (often farming; a relatively
high-risk activity), and the comparatively poor
transport facilities (ready access to a car is lower
in a rural population than an urban population).
As a result, health in rural areas is often
significantly worse than in towns, leading to
problems of social cohesion. The use of
telemedicine would enable a cost effective
delivery of service to meet the needs of rural
populations and thus increase social cohesion.
what has been achleved?
Compared to its potential, the achievements so
far have been disappointing: the promised radical
improvements in medical service delivery have
not been observed.
Success has been achieved in certain
'specialist'niches such as the provision of
difficult-to-access expertise to the US military and
the remote provision of expertise to ambulance-
men, which has improved the prognosis of crash
victims. However, these are relatively small-scale
specialist applications, unlikely to benefit the
'mass market'.
A recent survey of telemedicine applications
revealed a great number of initiatives and
schemes. These are all small, local projects
however, with liftle evidence of success in the
delivery of the benefis outlined. A list of projects
is given in Table 2. Although this survey was
conducted mainly in the UK, the projects
described are §pical of those in the rest of the EU
and elsewhere.
Many of the projects conducted in the EU
have been funded by various framework
programmes - mainly by the AIM (Advanced
The IPTS Report
The rapid availability of
remote expertise o'tFers
significant advantages
to rural areas and
would enhance social
cohesion
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Most of the research
initiatives underway
concentrate on testing
the concepts
underlying the
technology rather than
the possible health
service benefits
lnformatics in Medicine) initiative. This has run in
three phases. The first phase (1988 to 1990) was
exploratory in nature, being mainly concerned
with establishing the feasibility of advanced
informatics for health care. The second phase
(1991 to 1994) focused on developing the
underlying technology. The latest phase, part of
the fifth framework programme, will turn to the
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issue of patient and service benefits. Many of
these pro.jects have taken the form of 'proof of
concept' work, determining the technical
feasibility and usability of advanced telecoms in
health care. This focus on technology as opposed
to health or service benefits is one of the main
reasons for the lack of significant uptake and use
of telemedicine.
Ibble 2. Some Telem€dlclne Schomes
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What arc the obstacles?
The obstacles to further development and
adoption of this technology are the following:
. A fragmented market: different national health
services, different community §pes (e.g. rural
and urban), and different medical specialties
require different functions of a telemedicine
product. As a result the market for a particular
telemedicine product is likely to be small and
difficult to support cost effectively.
. Heterogeneous technology: there is little
standardization or commonality in health care
technology at present. A telemedicine service
would have to integrate with hundreds of
existing and different lT systems (for example,
Cermany uses 150 different Ceneral Practice
systems).
. Complexity of service delivery: some of the
services that are to be supported by
telemedicine are fiendishly complex (such as
radiology), meaning that the functionality of
the system is correspondingly difficult to
identify and provide.
. No standard economic framework: one of the
reasons why no pan-European study of the
health economic aspects of telemedicine has
been carried out is that different national
health services use very different economic
frameworks. For example, in Scandinavian
countries, patient time is costed whereas in
may others it is not.
o Untested legal framework: there are legal
issues that need to be resolved. For example,
should a telemedicine service be considered
as a form of drug with the legal implications
this implies, or merely the exchange of
expertise from one terminal of the service to
another.
. Lack of standards: in order to tame the
heterogeneous technical infrastructure alluded
to above, and in order that different
telemedical technologies can work with each
,-Jtt-J
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other, there is a need for technical standards to
be adopted. Although the standards body
CENTC25I has been in existence for many
years, there is still a long way to go before the
standards required for the more sophisticated
systems are agreed.
. Lack of continuity of funding: the introduction
of telemedicine services will require long term
commitment from funding bodies. To date this
has not been apparent, either in European or
national contexts. As a consequence, few
projects have managed to get beyond the pilot
stage, and many centres of excellence have
been disbanded (examples of promising
projects that have been 'killed' by short term
funding difficulties include TEAM and
Eurodiabeta).
All of these obstacles are greater the more
sophisticated the form of telemedicine service is.
The fact that they have held up progress tells us
that many proposed telemedicine schemes
depend on complex and advanced technology.
This is in spite of the fact that the more successful
pilots tend to use standard proven 'off the shelf'
technology.
This is part of the underlying reason for a lack
of widespread uptake of telemedicine, or indeed
any other health informatics product: the focus on
technology and the market rather than on need
and benefit.
There are two philosophies at work here. One
is the philosophy of the computer and
technology sector. The other that of the
medical/pharmaceutical sector. Telemedicine
work to date has been largely influenced by the
computer philosophy: Does the system work? ls it
affordable? ls it state-of-the-art? ls it 'user
friendly'? ls it reliable? Are the standards in place?
ls the market sufficiently large? These questions
are very difficult to answer in the light of the
The IPTS Report
Market fragmentation,
system complexity,
heterogeneiW, legal
uncertainty, lack of
standardization and
discontinuiW of
research funding are
among the problems
faced by telemedicine
pro9rammes
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The modelapplied in
the tech nologies sector
(state-of-the-art,
affordabiliW, user-
friendliness, etc.) does
not coincide with that
in the medical sector
(robust, safe, tested in
extensive f ield trials,
etc.)
problems described above. As a result the
enthusiasm of the technical community for
tackling the obstacles is limited.
ln any event technology will not be accepted by
the medical sector until the prime concern of the
other philosophy has not been answered: does it do
good? ln what way should the telemedicine service
be used to give health or rural cohesion benefits,
what are those benefits, and what models of service
delivery result in economic efficiencies (or at least in
a cost-neutral change)? These questions are very
different from those normally considered by the
technical communi§: they are, however, central to
the medical community which will not introduce a
new drug until it has proven itself in extensive field
trials. ln short, the model should not be the
computer usability test, but the pharmaceutical drug
trial. As a corollary to this, any such trial would
require robust and sable technologies rather than
those that are 'stateof-theart'.
Concluslons
The benefis to be gained from successful use of
telemedicine appear to be great. However, they are
currently unproven. The telemedicine debate has
too often been dominated by technical
considerations wi*r insufficient focus on the needs
of, and benefits for, the population that is to be
served: work has been 'technology driven' rather
than 'demand led'. As long as development and
introduction is left to the commercial sector, it will
stall. Often the work will need a large development
effort, for an uncertain return: that is, the commercial
market is insufficiently tempting for industry to be
willing to take all the risks alone. These risks must be
shared with those who have most to gain. This is, the
community itself and its agencies.
As long as the debate stays in the technical
camp it will not answer the key question: does
telemedicine do good? The debate should be
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passed to more relevant stakeholders: those with an
interest in the population's health, and those with
an interest in the reduction of rural isolation and
the increase in social cohesion.
From the point of view of the EU, it should be
pointed out that health care is outside the scope of
the Treaty of Rome. This might imply that EU policy
makers should focus on the potential benefis of
telemedicine to rural communities and the increase
in social cohesion that this might yield.
Major trials of the use of telemedicine are
needed, and these should be driven not only by
technologists or informaticians, but also by doctors
and representatives of beneficiaries. The trials
need to be extensive and honest, and determine
what the benefits are and how they are most
efficiently delivered, and demonstrate
convincingly that they have been delivered.
Furthermore, focusing on proof of benefit means
that it is not important to use 'cutting-edge' 'state-
of{he-art' technologies. Trials should use reliable
off-the-shelf technologies and simple applications
so that the message is not confused by the
technological barriers described above. Examples
of promising application areas are telemonitoring
and teleconsultation (which uses available
teleconferencing technology).
Commitment from policy makers and fund-
holders must be sincere, robust, and long-lasting:
the alternative is wasteful and will not create the
benefis argued for. lt is only when the evidence of
its effectiveness is sufficiently convincing that
telemedicine will be taken seriously by the
intended market and have a chance of delivering
the significant benefits claimed for it.
ln sho( the debate amongst European policy
makers concerning telemedicine has focused on
technology and markets. lts focus should be
extended to include health and social cohesion. 
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Minimally invasive
techniques allow
patients to return to
normal life more
rapidly, placing a lower
overall burden on the
health care system
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Minimally lnvasive Surg€ry:
Benefiting Patients and Health-Care
Systems
Marie-Laure Spaak, Patrick Urso, AD,f
Analysls
!nnovative medical technologies affect the
I or.fiV and cost of health care. They raise the
I issues of therapeutic efficacv, safetv, ethics.Ithe impact on health care services and overall
social effects. Minimally invasive techniques
specifically benefit society by lowering overall
medical expenses and benefit patients by
reducing discomfort. Since MIS techniques do not
entail major injury to the body, they produce less
pain and fewer scars. Patients can resume oral
food intake sooner, get back on their feet more
quickly, and consequently have a lower risk of
complications. ln most cases, one to three days of
hospitalization is sufficient; the recovery period is
also shorter. For instance, a patient who
undergoes laparoscopic appendectomy spends
three days in hospital and can go back to work
two weeks after the operation whereas
conventional surgery requires five days in hospital
and three weeks for recovery. The patient's sick
leave costs less for the national health care system
and disrupts his or her professional activities less.
Thus, although a minimally invasive operation
costs more at the outset (because the equipment is
disposable so can only be used once) the overall
cost of medical expenses is generally lower.
Another added advantage to these techniques is
the possibility of broadening indications to patients
who are in poorer physiological condition.
Routlne use ln certaln flelds
Certain universities (particularly in France and
Cermany), and private clinics pressured by patient
demand, were the first to use laparoscopic surgery.
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Today it has become a routine procedure for many
operations, especially for gynaecology and
abdominal surgery and for certain urologic
operations. lt is used for operations involving the
thorax, the spine and the pelvis, and can be used
for tumour ablation (gynaecology and digestive
endoscopy), uterine fibromas, ovarian cysts, the
gall-bladder or the appendix. Hernia repair and
loint surgery (arthroscopy) can be performed under
local anaesthesia with very small incisions.
Cynaecologicalobstetric surgeons have long used
scopes pioneered in laparoscopic operations. Cold
light sources and miniature cameras developed in
the eighties prompted other specialists to use these
techniques, since they could see their operations
on the video screen. With the astounding progress
that took place in medical imaging it was possible
to adapt minimally invasive techniques to a range
different fields such as neurosurgery,
gastroenterology, orthopaedic surgery urology,
cardiology, vascular surgery and oncology.
A new generatlon of surgeons
The widespread use of endoscopic techniques
requires surgeons skilled in new procedures, who
have reorganized their workspace to conduct
their image-guided operations with miniaturized
i nstruments includi ng endoscopes (optical tubes),
insertion devices (trocars) and other instruments
such as forceps, lancets, staplers, sutures, netdle-
holders, coagulators, ultrasound probes,
catheters, pressure sensors, etc.
This approach has revolutionized surgical
practice: the surgeon now operates remotely, so to
speak, guided by the image of the tissue. ln
addition, since the camera can be positioned
much closer to the structures being operated on,
the surgeon sees human anatomy in a new light,
with even more accuracy than during open
surgery. Training must be adapted to these new
aspects of surgery.
-J,J,J-J'
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ln order to perform such precise and delicate
manipulations, the surgeon not only needs the
technologies to offer a clear display of the internal
tissues, but also techniques providing hirilher with
essential sensorial (tactile, physical or chemical)
information. The physical conditions of the work
station must also be optimized (for instance, using
a robot to anchor the endoscope). Several research
teams throughout the world are tackling these
issues. These notions have led to a considerable
amount of current research on surgical robots to
assist the surgeon's hand with precision. ln
addition, the contribution of virtual reality will
allow practitioners to gain skills under excellent
training conditions and perform virtual operations
on surgical simulators.
italor rcsearch programmes addresslng
the lssue
Several research projects are under way in
Europe in the field of surgical robots and surgical
simulation, distance training for non-invasive
technìques and instrument miniaturization. ln
Cermany, the project endorsed by the BMBF
(Cerman ministry of higher education and research)
under the 'Mikrosystemtechnik' programme is
engineering a miniature endoscope with built-in
micro-optic components, optical fibres, and real-
time image processing technologies. The same
ministry has also funded the Aesculapcoordinated
MINOP project, with the goal of designing a
minimally invasive microneurosurgical instrument.
Creat Britain is also commifted to this research,
namely through a program financed by the Heahh
Ministry and supported by 1.2 million pounds of
funding, called 'Minimally lnvasive Therapy Video
Networking Project'. The programme includes
distance teaching of non-invasive surgical
techniques. ln France, the INRIA (lnstitut National
de Recherche en lnformatique et en Automatique) at
Sophia Antipolis, working on surgical robotics, and
the IRCAD (lnstitut de Rechreche contre le Cancers
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.o A number of projecb
in various European
countries are looking at
different aspects of
minimally invasive
surgery
A data network to
share medical
knowledge between
the different health
partners could be an
avenue for major
development
de l'Appareil Digestifl at Strasbourg are among the
worldt leading centres in the field of endoscopic
surgery. ln Cermany, the Kernforschungszentrum at
Karlsruhe is developing a surgery simulator.
The European ESPRIT programme is backing
projects in biomedicine on "standardization and
improvement of minimally invasive operating
techniques using advanced technologies such as
miniaturization, 3D imaging, robotization, video
techniques, microstructure techniques and assisted-
surgery nanotechniques".
Beyond major existing programmes and
projects already being funded, several actions
could be launched to support medical research in
this field, which suffers from the lack of means
compared with the needs of practitioners. Surgical
robots and simulators, for example, are still an issue
for the future and the development required for
these technologies to be able to enter routine use is
considerable.
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ln this context, it would be worthwhile for
Europe to support the development of a technology
monitoring centre. This centre could create an
information platform and use the resources of
existing networks, regularly informing different
(private, scientific, institutional, etc.) European
partners working in the field on world-wide
advances in medical technologies. lnformation
could be disseminated, for example, with a
monitoring bulletin or by creating an lnternet site
for minimally invasive surgery.
ln this light, installing a data network to share
medical knowledge (scientific advances,
technological developments, legislation, research
programmes and projects, etc.) between the
different health partners could also be an avenue
for major development allowing improved
diagnostic and therapeutic methods. Such a
network would nevertheless require a large
investment at the beginning. An example of a
network of this type is CICE (Centre lnternational
.J'-J'.J
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de Chirurgie Endoscopique), which is the
reference point for a network comprising other
university centres in Europe carrying out similar
activities: Heidelberg, Barcelona, Brussels,
Milan, Palermo, Bratislava, Moscow. lt also
maintains a close relationship with universities in
the United States (Stanford), Vietnam,
Montevideo, and China. lt should be noted that
the European Community already supports
projects for the development of information
networks applied to the field of medicine; among
these is the TEN Telemed (Trans-European
Network) whose goal is to promote education.
Concluslon
More than ever before, surgeons today need
teaching tools adapted to allow rapid learning of
new operating techniques. The demand for more
know-how is great. Availability of equipment
and training materials (video-conferences,
distance training sessions...) among others, will
play a dominant role. EU-level support for the
development of structures adapted to these
needs could be crucial.
With the promised reduction in overall cost
of patient management, minimally invasive
techniques can help both medically and
financially, beyond the impact on individual
patients. There are positive externalities
involved for society (in terms of social
expenditure), which would justify public
intervention, although the impact on different
national health care systems is likely to vary. ln
any case, the acquisition of hospital equipment
and initiatives for physician training deserve to
be supported. f
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BRIEF NOTE
Astrid Zwick
Envlronment and Health
I n article about the relationship between
I health and climate in the April issue of the
fl tffs report presented some statistics andI lpredictions for a global warming scenario
(Zwick,1997l. The consequences are serious, not
only due to the direct thermal impact but also on
account of an increase in temperature causing the
shifting of vectors that transmit diseases to areas
previously uninfected. Moreover, modern travel
may turn tropical diseases into real threats for
usually safe areas in the subtropical and
temperate regions. ln addition, extreme weather
events, like droughts and subsequent heavy
precipitation could cause the spreading of viral
diseases like the hantavirus epidemic in the USA.
There are more threats and synergies with
other environmental factors like air, soil and water
pollution, the population's health status, the state
of hygiene, population density and growth. ln
industrialized countries the increase of allergic
disorders is striking. The case is serious since
almost all natural compartments (atmosphere,
soil, water) are more or less polluted by human
activities. Not enough is known about the dose-
effect relationship to justify prevention and
treatment levels. More needs to be known on the
epidemiology of modern pollution factors,
tolerance levels and effect thresholds.
A European Commission proposal on an
action programme for pollution-related diseases
has been put forward in order to draw more
aftention on the prevention of diseases related to
environmental pollution. lt has been noted that
one in three Europeans suffer from an allergy and
this proportion is rising, translating into rising
health-care costs.
The situation could be mitigated through
improvement of the information about the relation
between human health and environmental
pollution through enhanced research; reduction
of exposure through pollution prevention,
avoidance and control; surveillance to help
avoidance (monitoring and early warning
systems), as well as, obviously, through treatment
of related symptoms. f
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environment, health, climate, exposure, pollution prevention
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